Avalo Therapeutics (AVTX) Equity Ratio (2016 - 2025)
Avalo Therapeutics' Equity Ratio history spans 12 years, with the latest figure at 0.71 for Q4 2025.
- For Q4 2025, Equity Ratio fell 19.2% year-over-year to 0.71; the TTM value through Dec 2025 reached 0.71, down 19.2%, while the annual FY2025 figure was 0.71, 19.2% down from the prior year.
- Equity Ratio reached 0.71 in Q4 2025 per AVTX's latest filing, down from 0.73 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.89 in Q1 2025 to a low of 0.91 in Q1 2024.
- Average Equity Ratio over 5 years is 0.24, with a median of 0.31 recorded in 2021.
- Peak YoY movement for Equity Ratio: skyrocketed 1004.75% in 2023, then tumbled 425.91% in 2024.
- A 5-year view of Equity Ratio shows it stood at 0.29 in 2021, then tumbled by 213.68% to 0.33 in 2022, then surged by 206.36% to 0.35 in 2023, then surged by 153.67% to 0.88 in 2024, then dropped by 19.2% to 0.71 in 2025.
- Per Business Quant, the three most recent readings for AVTX's Equity Ratio are 0.71 (Q4 2025), 0.73 (Q3 2025), and 0.83 (Q2 2025).